Navigation Links
Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on 'Zero Tolerance for Hepatitis B'
Date:5/20/2008

Spotlights National Hepatitis B Awareness Week

DOYLESTOWN, Pa., May 20 /PRNewswire-USNewswire/ -- Recognizing National Hepatitis B Awareness Week May 19 - 23, 2008, the Hepatitis B Foundation and the Association of Asian Pacific Community Health Organizations (AAPCHO) is hosting a Congressional briefing, "Zero Tolerance for Hepatitis B: the Health Needs of Women and Children," on May 20 at the U.S. Capitol with special guests Congressmen Mike Honda (CA) and Charles Dent (PA). It will call urgent attention to the health needs of pregnant women infected with hepatitis B and the protection of their newborns against this deadly virus. Patients and experts from the CDC and Johns Hopkins University Hospital have been invited to testify.

"With the availability of an effective vaccine and six approved therapies for chronic hepatitis B, no woman or child should be left behind," says Dr. Timothy Block, co-founder and president, Hepatitis B Foundation. With good vaccines and treatment options, the U.S. has the tools to effectively implement a zero tolerance policy against hepatitis B to protect the health of Americans.

Hepatitis B is the deadliest disease that can be prevented through infant vaccination. In the U.S., approximately 20,000 babies are born yearly to women with hepatitis B. Despite a national requirement that all newborns be vaccinated at birth against the hepatitis B virus (HBV), up to 1,500 newborns are chronically infected with HBV. Twenty-five percent will die prematurely from liver failure or cancer, usually in the prime of their adult lives.

There are national guidelines requiring all pregnant women be tested for hepatitis B and recommendations to educate and refer infected women to care. Local and state health departments lack necessary resources to implement the recommendations. According to Jeff Caballero, executive director, AAPCHO, "This gap in care results in jeopardizing the health of these infected women and continues the devastating cycle of maternal HBV transmission between mother and her newborn."

Hepatitis B is the world's most serious common liver infection transmitted through blood, sex, drug use, and from an infected woman to her newborn. It is the primary cause of liver cancer, which is the fastest growing cancer in the U.S. Worldwide, one million people die from hepatitis B each year.

Guest speakers at the May 20 Congressional briefing include Dr. Kathleen Schwarz, director, Pediatric Liver Center, Johns Hopkins University School of Medicine; Dr. Mack Mitchell, chief, Division of Gastroenterology, Johns Hopkins Bayview Medical Center; Dr. Chong Gee Teo, chief, Laboratory Branch, Division of Viral Hepatitis, CDC; Mr. Ted Fang, director, AsianWeek Foundation; and personal testimonies from California Assemblywoman Fiona Ma and Lucy C.

Hepatitis B Foundation is dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide. http://www.hepb.org.

Association of Asian Pacific Community Health Organizations represents community health organizations dedicated to the health of Asian Americans. http://www.aapcho.org.

Contact: Leah Rice

215-340-0480 / leah@furiarubel.com Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Dr. Timothy Block http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=66704 Joan Block http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=66707


'/>"/>
SOURCE Hepatitis B Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
4. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
6. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
7. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
10. Oncolys BioPharma and Tacere Therapeutics Sign Strategic Alliance and License Agreement to Develop and Commercialize RNAi Hepatitis C Drug
11. XTL Biopharmaceuticals Signs $108 Million Deal for the Licensing of its Pre- Clinical Program in Hepatitis C to Presidio Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree ... products targeting the needs of consumers who are incorporating medical marijuana into their ... Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s ...
(Date:10/7/2017)... (PRWEB) , ... October 06, ... ... years’ experience providing advanced instruments and applications consulting for microscopy and surface ... expertise in application consulting, Nanoscience Analytical offers a broad range of contract ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). ... Institute. The event is free and open to the public, but registration is ...
Breaking Biology Technology:
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):